汉佩生物完成千万元级融资 重庆政府引导性种子基金“育苗”见效

Core Insights - Chongqing Hanpei Biotechnology Co., Ltd. has completed a Pre-A round financing of tens of millions of yuan, marking the largest single financing case in the seed fund support project by the Chongqing Liangjiang Industry Group [1] - The financing indicates a significant breakthrough in the Chongqing government's seed fund efforts to cultivate early-stage technology projects and facilitate the transformation of scientific achievements [1] Company Overview - Hanpei Biotechnology focuses on the pet economy, which is projected to reach a market size of over 300 billion yuan in the urban pet medical market by 2024, with a year-on-year growth of 5.6% [3] - The company aims to address the supply-demand mismatch in the high-end pet medication market, where domestic products face challenges from international giants [3] Talent and Innovation - The core technical team of Hanpei Biotechnology consists of over 50% PhD holders and 70% master's degree holders, including leaders from major universities and national key project scientists [4] - The company has developed a long-acting antibiotic for pets, which has received national certification, and is working on next-generation antibiotic products [5] Market Position and Strategy - Hanpei Biotechnology is dedicated to creating a leading domestic platform for high-end veterinary drug innovation, focusing on first-in-class and best-in-class pet medications [6] - The company has over 20 new drug candidates in development, including three national class I new veterinary drugs, with a focus on various therapeutic areas [5] Government Support and Funding - The early investment from the Chongqing seed fund has provided a solid foundation for Hanpei Biotechnology, enabling technology validation and initial research [7] - The investment model of the seed fund has proven effective in reducing investment concerns from social capital, supporting over 50 projects across various cutting-edge industries [7] Future Prospects - With the influx of funds from the recent financing, Hanpei Biotechnology is accelerating the clinical development of innovative drugs for pet infections and gastrointestinal diseases, aiming to reshape the domestic pet pharmaceutical market [8]